Sinovac Biotech, Accounts Payable

The latest accounts payable for SVA is $16M as of December 2025. Investors often review this figure alongside Sinovac Biotech,'s historical trend and sector peers before judging valuation or financial health.

A accounts payable figure of $16M for SVA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SVA's accounts payable ($16M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Sinovac Biotech,'s accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.